FDA approves the first generic Qsymia

The U.S. Food and Drug Administration approved the first generic version of Qsymia — phentermine and topiramate extended-release capsules — on June 25, 2024 ^[2]. Qsymia is an oral weight-loss medication approved for certain adults and adolescents ages 12 and older ^[2].

The approval came through an abbreviated new drug application, ANDA 204982 ^[2]. Approval, though, did not mean immediate availability. The generic could not launch right away, and it did not reach U.S. pharmacies until May 7, 2025, when it was listed among Teva's recent product launches ^[2]. Teva completed its acquisition of Actavis Generics in 2016 ^[2]. Brand-maker Vivus had previously announced a settlement with Actavis over Qsymia patent litigation, according to references cited by GoodRx ^[2].

First generics matter to the FDA for a specific reason: the agency says it prioritizes review of these applications because they create more affordable treatment options for patients ^[1]. A first generic is simply the first approval that lets a manufacturer market a generic version of a given drug in the United States ^[1]. The FDA also cautions that approved drugs are not always available on or after the listed approval date — which is exactly what happened here, with roughly ten and a half months between approval and launch ^[1][2].

What the price difference looks like

Generic medicines are typically priced below their brand-name counterparts, and they are often preferred over brand-name drugs on insurance formularies, which are the lists of medications a plan covers ^[2].

With a free GoodRx coupon, the price of generic phentermine/topiramate ER has been listed as low as $59.05 at certain pharmacies ^[2]. For the brand, GoodRx lists an exclusive cash price of $149.10 for a 30-day supply at the 7.5 mg/46 mg strength ^[2]. Other brand routes include a manufacturer copay card that can bring costs to as little as $70 for people who are eligible and whose insurance covers the drug, and a home-delivery option through the Qsymia Engage program at as little as $98 for cash-paying patients ^[2].

In some cases, the brand may still cost less than the generic depending on a person's plan and eligibility for savings programs ^[2]. Coverage is not guaranteed: not all insurance plans cover weight-loss medications, and a prior authorization may be required ^[2].

Why it matters for patients

Most people weighing weight-loss drug options in the U.S. are looking at injectable GLP-1 medicines such as semaglutide (Wegovy) and tirzepatide (Zepbound), where lower-cost generics are years away for most products ^[2]. Qsymia is an older oral option, and its generic entry gives prescribers and patients a pill that can be filled at a two-figure cash price at some pharmacies ^[2].

Practical consequences are mostly financial and logistical. Insurance plans frequently steer patients toward generics, so people already taking brand-name Qsymia may find their cost-sharing changes ^[2]. Pharmacies may also take time to stock a newly launched generic, so availability can vary by location ^[2].

These sources do not compare how much weight people lose on phentermine/topiramate versus GLP-1 medicines, and they do not describe side effects, safety warnings or who should avoid the drug. Those questions are not answered here.

What happens next

First generics are eligible for a 6-month exclusivity period as the only generic version on the market ^[2]. After that window closes, additional manufacturers can launch their own versions, and the FDA notes that more competition tends to push prices down further ^[2].

Exactly when additional phentermine/topiramate ER generics will arrive, and what they will cost, is not stated in these sources. Anyone comparing prices can check with their insurer and pharmacist, since a pharmacist or pharmacy technician can help identify the lowest available price on a prescription ^[2].